Trulicity (Dulaglutide) in Adolescents Age 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

What "Off-Label" Means for Dulaglutide in Teens

Dulaglutide carries FDA approval for glycemic control in adults with type 2 diabetes, with no approved pediatric labeling. Off-label means the prescriber is acting outside the package insert's approved population. That is a legal, common, and sometimes evidence-supported practice, but it shifts the burden of clinical justification entirely onto the provider.

The Regulatory Baseline

The FDA approved Trulicity in September 2014 for adults. The prescribing information explicitly states the safety and efficacy of dulaglutide have not been established in patients younger than 18 years. [1] No pediatric exclusivity extension or supplemental approval for the 12 to 17 age band has been granted as of this writing.

Off-label prescribing is not prohibited. The FDA does not regulate the practice of medicine, and clinicians may prescribe approved drugs for unapproved populations when clinical judgment supports it. The American Academy of Pediatrics has published guidance acknowledging that off-label use is common in pediatric practice precisely because trials in children lag behind adult drug development. [2]

Why Adolescent Type 2 Diabetes Needs Better Options

Type 2 diabetes in youth is not a mild version of adult disease. The TODAY study (N=699) showed that 50% of youth randomized to metformin alone lost glycemic control within 3.9 years of diagnosis. [3] Compared to adults, teens with type 2 diabetes progress faster, develop complications earlier, and respond less robustly to oral agents. That clinical urgency explains why clinicians sometimes reach for agents not yet formally approved for this population.

AWARD-PEDS: The Core Pediatric Evidence for Dulaglutide

AWARD-PEDS (NCT01948908) is the phase 3 randomized controlled trial that forms the primary evidence base for any clinical discussion of dulaglutide in patients aged 10 to 17. It is the closest thing to a registration-quality dataset for this off-label use.

Trial Design and Population

AWARD-PEDS enrolled 154 pediatric patients (ages 10 to 17) with type 2 diabetes who had inadequate glycemic control on diet and exercise alone or on stable metformin or insulin. Participants were randomized 1:1:1 to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or placebo, all added to background therapy. The primary endpoint was change in HbA1c from baseline to 26 weeks. [4]

Mean baseline HbA1c was approximately 8.0%. Roughly 60% of participants were on metformin background therapy. This matters for generalizability: the population was relatively early in their disease course, not patients who had exhausted multiple lines of therapy.

Efficacy Results

At 26 weeks, dulaglutide 0.75 mg produced a mean HbA1c reduction of −0.63% versus +0.64% in the placebo group (treatment difference −1.27%, P<0.001). The 1.5 mg dose produced a −0.78% reduction versus the same placebo trajectory (treatment difference −1.42%, P<0.001). [4]

Both doses were statistically superior to placebo. The difference between the two active doses was not statistically significant, which mirrors the modest dose-response relationship seen in adult AWARD trials.

Weight change was modest. The 1.5 mg group showed a mean change of −0.87 kg versus +0.56 kg in the placebo group. This is a small absolute effect, but adolescents with type 2 diabetes are typically overweight or obese, and avoiding further weight gain during treatment carries its own clinical value. [4]

What AWARD-PEDS Cannot Tell Us

The trial ran only 26 weeks. Long-term cardiovascular outcomes, nephropathy progression, and durability of HbA1c response beyond 6 months were not assessed. The sample size of 154 was powered for glycemic endpoints, not safety signals. Rare adverse events would not be detectable at that N.

Safety Profile in the 12 to 17 Age Band

Understanding the safety signal in pediatric patients requires looking at both AWARD-PEDS data and the broader adult pharmacovigilance record, since the mechanism of action does not change with age.

Gastrointestinal Adverse Events

In AWARD-PEDS, gastrointestinal adverse events were the most common reason for discontinuation in the dulaglutide arms. Nausea was reported in approximately 17% of the 1.5 mg group versus 7% of the placebo group. Vomiting occurred in roughly 12% versus 4%, respectively. [4] These rates are directionally consistent with adult trial data from AWARD-11 and other adult AWARD studies, suggesting the GI tolerability profile in adolescents is not markedly worse than in adults.

Clinicians should counsel families that GI symptoms typically peak in weeks 1 to 4 and attenuate with continued use. A slow titration strategy (starting at 0.75 mg for at least 4 weeks before considering uptitration) is standard practice in adults and was the approach used in AWARD-PEDS.

Hypoglycemia Risk

Documented symptomatic hypoglycemia occurred in 11% of the 1.5 mg group versus 6.7% of the placebo group, though most cases were mild. [4] The risk rose in participants who were also on insulin background therapy. When prescribing dulaglutide off-label in an adolescent already on insulin, dose reduction of the insulin component should be discussed proactively to reduce hypoglycemia risk.

Pancreatic and Thyroid Considerations

The FDA requires a boxed warning for all GLP-1 receptor agonists regarding the risk of thyroid C-cell tumors observed in rodent studies. The clinical relevance in humans remains uncertain, but the warning applies equally to pediatric off-label use. Dulaglutide should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [1]

Pancreatitis has been reported with dulaglutide in adults. AWARD-PEDS did not report cases of pancreatitis, but the trial was underpowered to detect this signal. Any adolescent presenting with persistent abdominal pain while on dulaglutide should be evaluated promptly for pancreatitis.

Renal Function Monitoring

Dulaglutide is not renally cleared and does not require dose adjustment for renal impairment per the adult label. However, GI-related dehydration can transiently worsen renal function, especially in adolescents with pre-existing diabetic nephropathy. Annual serum creatinine and urine albumin-to-creatinine ratio monitoring is reasonable clinical practice. [1]

Dosing Considerations for Adolescents

No pediatric dose has been formally approved. The doses studied in AWARD-PEDS (0.75 mg and 1.5 mg weekly) are identical to the two lower doses in the adult-approved range (which extends up to 3.0 mg and 4.5 mg for adults with type 2 diabetes). [1]

Practical Dosing Protocol Used in AWARD-PEDS

• Starting dose: 0.75 mg subcutaneous injection once weekly
• Uptitration timing: After a minimum of 4 weeks at 0.75 mg, clinicians in the trial could increase to 1.5 mg based on glycemic response and tolerability
• Injection sites: Abdomen, thigh, or upper arm; rotate sites each week
• Administration: The single-dose autoinjector pen does not require reconstitution, which simplifies administration for adolescent patients and their caregivers

Body weight-based dosing was not used in AWARD-PEDS, and no weight-based pediatric dosing algorithm has been published for dulaglutide. This contrasts with some other pediatric drug approvals where weight-based dosing is standard.

Timing and Food Interactions

Dulaglutide can be taken without regard to meals, which improves adherence in adolescent populations who may have irregular eating patterns. The once-weekly injection schedule is also a practical advantage over daily injectable options.

How Dulaglutide Compares to Approved Options in This Age Band

Prescribers considering off-label dulaglutide should first confirm whether an approved alternative is viable.

Approved GLP-1 Options for Adolescents

Exenatide extended-release (Bydureon BCise) received FDA approval in October 2021 for patients aged 10 years and older with type 2 diabetes. [5] It is dosed as 2 mg subcutaneous weekly. This is the only weekly GLP-1 receptor agonist with a formal pediatric approval for glycemic control in this age group, making it the first-line GLP-1 consideration before reaching for dulaglutide.

Liraglutide (Victoza) received FDA approval in 2019 for patients aged 10 years and older with type 2 diabetes, dosed at up to 1.8 mg daily. [6] The ELLIPSE trial (N=134) demonstrated significant HbA1c reduction in this population. Daily injection is a drawback compared to weekly agents.

Semaglutide 2.4 mg (Wegovy) received FDA approval in December 2022 for chronic weight management in adolescents aged 12 years and older with obesity (BMI at or above the 95th percentile). [7] The STEP TEENS trial (N=201) showed 16.1% reduction in BMI at 68 weeks versus 0.6% with placebo. [8] For an adolescent whose primary concern is obesity with comorbid insulin resistance, semaglutide 2.4 mg has a stronger evidence base and a formal approval.

When Off-Label Dulaglutide Might Still Be Considered

A prescriber may reasonably consider off-label dulaglutide in an adolescent aged 12 to 17 under the following specific circumstances:

1. Exenatide ER and liraglutide have been tried and failed to achieve glycemic targets, or caused intolerable side effects
2. The patient's primary indication is glycemic control, not weight management (which would favor semaglutide 2.4 mg)
3. Insurance prior authorization for an approved agent has been denied and dulaglutide is accessible at lower cost
4. The prescriber documents the clinical rationale, obtains informed consent from both the patient and guardian, and establishes a monitoring plan

The Endocrine Society's 2018 clinical practice guideline on pediatric obesity notes that treatment decisions in youth should be individualized and guided by the best available evidence, even when that evidence is from trials not yet supporting full approval. [9]

Informed Consent and Documentation Requirements

Off-label prescribing in minors carries a higher documentation burden than standard adult prescribing. Both the adolescent patient (age-appropriate assent) and a parent or legal guardian must be informed that the medication is not FDA-approved for the patient's age group.

What the Consent Discussion Should Cover

• The FDA has not approved dulaglutide for patients under 18 years
• The available data come from a 26-week trial of 154 participants
• Long-term safety data in adolescents are not available
• Approved alternatives exist and should be discussed by name
• The specific risks particular to this patient (e.g., concurrent insulin use, family history of thyroid cancer)

Documentation in the medical record should include the indication, why approved alternatives were not chosen or were insufficient, the consent discussion, and the monitoring plan. Some state medical boards and hospital credentialing bodies have specific policies about off-label prescribing documentation. Clinicians should verify local requirements.

Monitoring Protocol for Adolescents on Dulaglutide

A structured monitoring protocol reduces risk and provides the data needed to evaluate treatment success.

Glycemic Monitoring

HbA1c should be measured at baseline, at 12 weeks (to assess early response), and every 3 months thereafter. Fasting plasma glucose or continuous glucose monitor data, where available, can supplement HbA1c in adolescents with atypical hemoglobin variants that may affect HbA1c accuracy. The American Diabetes Association's 2024 Standards of Care recommend an HbA1c target of <7.0% for most youth with type 2 diabetes when this can be achieved without significant hypoglycemia. [10]

Growth and Weight Surveillance

Adolescence is a period of active growth. Weight, height, and BMI percentile should be tracked at every visit. The modest weight-neutral to weight-lowering effect of dulaglutide at doses studied in AWARD-PEDS is unlikely to compromise linear growth, but no long-term data confirm this. Any unexpected changes in growth trajectory should prompt re-evaluation.

Thyroid and Abdominal Symptom Screening

At each visit, ask specifically about neck masses, dysphagia, or hoarse voice (potential signs of thyroid C-cell pathology) and about persistent or severe abdominal pain (potential pancreatitis). These are low-probability events, but the boxed warning obligates active surveillance.

Practical Guidance for Families and Caregivers

Adolescents are more likely to maintain injection adherence when they understand the rationale and feel agency in the decision.

Injection technique should be demonstrated in the office and confirmed at the first follow-up. The Trulicity single-dose pen is designed to reduce needle-phobia barriers: the needle is hidden before, during, and after injection, which tends to improve acceptance in teenagers. [1]

A 3-month injectable sharps container should be provided or prescribed at initiation. Sharps disposal education is a practical necessity that is often overlooked in busy clinic settings.

GI symptoms in the first 4 weeks should be managed with dietary adjustments: smaller, lower-fat meals, reduced carbonated beverages, and hydration. Families should know that stopping the medication during the first few weeks because of nausea is the most common reason for treatment failure, and that the symptoms typically resolve.

Insurance and Access Considerations

Dulaglutide is available as a branded product (Trulicity) with no generic currently on the US market. A 4-week supply carries a list price above $800. Most commercial insurance plans cover Trulicity for adults with type 2 diabetes, but prior authorization for off-label pediatric use is frequently denied on the first submission.

Eli Lilly's patient assistance program (Lilly Insulin Value Program) does not cover Trulicity; a separate Lilly Cares Foundation program covers non-insulin products for qualifying patients. Prescribers pursuing off-label dulaglutide in adolescents should initiate insurance appeals with documentation of AWARD-PEDS data and documented failure of approved agents.